Der-Petrossian M, Seeber A, Hönigsmann H, Tanew A
Department of Dermatology, Division of Special and Environmental Dermatology, University of Vienna Medical School, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
Br J Dermatol. 2000 Jan;142(1):39-43. doi: 10.1046/j.1365-2133.2000.03239.x.
In patients with severe chronic atopic dermatitis (AD), both photochemotherapy [psoralen ultraviolet A (PUVA)] and narrow-band (TL-01) UV B phototherapy have been reported to be very effective. As no data exist on the relative therapeutic efficacy of these two regimens, we performed a randomized investigator-blinded half-side comparison study on 12 patients with severe chronic AD. Half-side irradiation with threshold erythemogenic doses of 8-methoxypsoralen bath-PUVA and narrow-band UVB was performed three times weekly over a period of 6 weeks. The severity of the disease was assessed separately for the paired halves of the patients' bodies by a modified SCORAD score at baseline and after 2, 4 and 6 weeks of treatment. Ten of the 12 patients completed the trial. All but one showed marked improvement or complete remission with both treatments. The mean baseline SCORAD score decreased by 65.7% by the bath-PUVA treatment and by 64.1% by the narrow-band UVB treatment (P = 0.48). No serious adverse reactions to either of the two regimens were observed. Our data confirm the high efficacy of bath-PUVA and narrow-band UVB phototherapy in the treatment of patients with chronic severe AD. Both regimens appear to be equally effective when administered in equi-erythemogenic doses.
在重度慢性特应性皮炎（AD）患者中，光化学疗法[补骨脂素紫外线A（PUVA）]和窄谱（TL-01）UVB光疗均已被报道非常有效。由于尚无关于这两种治疗方案相对疗效的数据，我们对12例重度慢性AD患者进行了一项随机、研究者盲法的半侧对照研究。用阈红斑量的8-甲氧基补骨脂素浴用PUVA和窄谱UVB对患者身体的半侧进行照射，每周3次，共6周。在基线以及治疗2、4和6周后，通过改良的SCORAD评分分别对患者身体的配对半侧的疾病严重程度进行评估。12例患者中有10例完成了试验。除1例患者外，其余所有患者在两种治疗下均显示出明显改善或完全缓解。浴用PUVA治疗使平均基线SCORAD评分降低了65.7%，窄谱UVB治疗使平均基线SCORAD评分降低了64.1%（P = 0.48）。未观察到对两种治疗方案中任何一种的严重不良反应。我们的数据证实了浴用PUVA和窄谱UVB光疗在治疗慢性重度AD患者中的高效性。当以等红斑量给药时，两种治疗方案似乎同样有效。
